NCT04793399终止1 期
Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2021年2月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Safety Profile of Bosutinib 400 mg Daily in Combination With Atezolizumab in Participants With Chronic Myeloid Leukemia as First Line Treatments
研究概览
简要总结
The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and therefore treatment discontinuation probabilities in these patients. We propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.
详细描述
The combination of bosutinib and atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and consequently treatment discontinuation probabilities in these patients. We would like to propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient ≥ 18 years of age.
- •Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.
- •Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •Newly Patient with Philadelphia chromosome positive chronic phase CML and BCR-ABL1 transcript detected at diagnosis.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or
- •Adequate hepatic, renal and pancreatic function defined as:
- •Total bilirubin within normal range or Direct bilirubin ≤ 1.5 x ULN,
- •Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) or ≤5 x ULN if attributable to liver involvement of leukemia,
- •Women of childbearing potential must have a negative pregnancy test documented prior enrollment. Women of childbearing potential and men must be using an adequate method of contraception.
排除标准
- •Pregnant or lactating women,
- •Participation in another clinical trial with any investigational drug within 30 days prior to study enrollment,
- •Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea,
- •Period of time since CML diagnosis longer than 6 months,
- •Hypersensitivity to the active substances or to any of the excipients of the bosutinib and/or atezolizumab formulations,
- •Major surgery or radiotherapy within 14 days of enrollment,
- •Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease,
- •Concomitant use of or need for medications known to prolong the QTc interval,
- •Concomitant use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin), moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem), or strong CYP3A inducers (rifampin, carbamazepine, phenytoin),
- •History of clinically significant or uncontrolled cardiac disease, including:
- •Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure.
- •Myocardial infarction within the previous 6 months,
- •Symptomatic cardiac arrhythmia requiring treatment,
- •Diagnosed or suspected congenital or acquired prolonged QT history or prolonged QTc. (QTcF should not exceed 500 msec),
- •Grade III or IV fluid retention,
- •Uncontrolled hypomagnesemia or uncorrected symptomatic hypokalemia, due to potential effects on the QTc interval,
- •Uncontrolled or symptomatic hypercalcemia,
- •Recent or ongoing clinically significant gastrointestinal (GI) disorder e.g. Crohn's Disease, Ulcerative Colitis or prior total or partial gastrectomy,
- •Autoimmune or infectious active disease that require treatment,
- •CML patient not in chronic phase at diagnosis,
- •Patients with known atypical transcript. An atypical transcript is defined by the presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and b2a2 (e13a2) or p210 protein,
- •Patients with known resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V). It is not necessary to perform mutation tests on the patient to be included in the study if they were not previously performed,
- •Individuals with an active malignancy,
- •Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive) and/or hepatitis C.
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.
- •Patients with severe renal impairment
研究组 & 干预措施
Bosutinib-Atezolizumab Combination
Experimental
Drugs to be administered:
Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year
干预措施: Bosutinib 400 MG Monotherapy (Drug)
Bosutinib-Atezolizumab Combination
Experimental
Drugs to be administered:
Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year
干预措施: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection (Drug)
结局指标
主要结局
Safety Profile of Bosutinib 400 mg Daily in Combination With Atezolizumab in Participants With Chronic Myeloid Leukemia as First Line Treatments
时间窗: through study completion, up to 7 months
All Adverse Events, despite their severity or causal relationship with the study medication, will be reported, graded according CTCAE v5.0 and analyzed.
次要结局
- The Rate of Confirmed MR4 and MR4.5(7 months)
- Days to Response (CCyR, MMR, MR4, MR4.5)(7 months)
- Phenotypical Assays of Differentiation, Maturation and Proliferation NK Cells Markers(7 months)
- To Evaluate the Molecular Response (MR) Rates(7 months)
- The Rate of Complete Cytogenetic Response (CCyR)(7 months)
- Number of Overall Surviving Patients(7 months)
- Number of Complete Cytogenetic Responses (CCyR)(7 months)
- Number of Progression-free Survival Patients(7 months)
- Phenotypical Assays of Cell Characterization(7 months)
- Phenotypical Assays of Predictive Markers of CML Relapse(7 months)
- The Median Time to Response (CCyR, MMR, MR4, MR4.5)(7 months)
- Probability of Response (CCyR, MMR, MR4, MR4.5)(7 months)
- Number of Failure-free Survival Patients(7 months)
- Number of Event-free Survival Patients(7 months)
- Percentage of Participants Alive(7 months)
- Number of Confirmed MR4 and MR4.5(7 months)
- Phenotypical Assays of CD4+ T Cells Activation Markers(7 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT02846623M.D. Anderson Cancer Center50
进行中（未招募）
2 期
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasNon-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Nodal Marginal Zone LymphomaAnn Abor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Nodal Marginal Zone LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Nodal Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent Non-hodgkin LymphomaStage II Splenic Marginal Zone LymphomaStage III Splenic Marginal Zone LymphomaStage IV Splenic Marginal Zone LymphomaNCT03198026Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University29
招募中
2 期
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCPapillary Renal Cell Carcinoma Type 2NCT05096390Centre Leon Berard72
已完成
2 期
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsSkin Squamous Cell CarcinomaAppendix AdenocarcinomaRare LesionLocally Advanced Malignant NeoplasmLocally Advanced Skin Squamous Cell CarcinomaMetastatic Malignant NeoplasmMetastatic Skin Squamous Cell CarcinomaMetastatic Small Intestinal AdenocarcinomaRare Neoplastic SyndromeRefractory Malignant NeoplasmStage IV Small Intestinal Adenocarcinoma AJCC v8Unresectable Malignant NeoplasmNCT03108131M.D. Anderson Cancer Center49
进行中（未招募）
2 期
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8NCT03600701National Cancer Institute (NCI)53